COST SAVINGS IN TYPE-2 DIABETES (T2D) WITH INSULIN GLARGINE COMPARED WITH INSULIN DETEMIR IN THE UNITED KINGDOM

被引：0
|
作者：
Tilling, C. [1 ]
Evans, L. M. [2 ]
Keech, M. [3 ]
机构：
[1] Sanofi Aventis, Guildford, Surrey, England
[2] Univ Hosp Llandough, Penarth, S Glam, Wales
[3] Pharmakos, St Albans, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.536
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A96 / A96
页数：1
相关论文
共 50 条
  • [1] Cost Savings in Type 2 Diabetes with Insulin Glargine Compared with Insulin Detemir in the UK
    Evans, Marc
    Owens, David
    Carroll, Dawn
    Keech, Martin
    [J]. DIABETES, 2009, 58 : A517 - A517
  • [2] Cost-effectiveness analysis of insulin detemir compared to NPH insulin in patients with type-2 diabetes in the United Kingdom
    Smith, I
    Palmer, AJ
    Roze, S
    Kennedy-Martin, T
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 735 - 736
  • [3] COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN A BASAL SUPPORTED ORAL THERAPY (BOT) IN GERMANY
    Neilson, A.
    Pscherer, S.
    Dippel, F. W.
    Dietrich, E. S.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A408 - A408
  • [4] Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 2 Diabetes (T2D)
    Hollander, Priscilla
    Golm, Gregory
    Carofano, Wendy
    Eldor, Roy
    Crutchlow, Michael
    Marcos, Michael
    Rendell, Marc
    Home, Philip
    Gallwitz, Baptist
    Rosenstock, Julio
    [J]. DIABETES, 2016, 65 : A238 - A238
  • [5] Insulin detemir versus insulin glargine for type 2 diabetes mellitus
    Simon, A. C. R.
    Swinnen, S. G.
    Holleman, F.
    Hoekstra, J. B. L.
    DeVries, J. H.
    [J]. DIABETOLOGIA, 2011, 54 : S420 - S421
  • [6] Insulin detemir versus insulin glargine for type 2 diabetes mellitus
    Swinnen, Sanne G.
    Simon, Airin C. R.
    Holleman, Frits
    Hoekstra, Joost B.
    DeVries, J. Hans
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (07):
  • [7] Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes
    Hompesch, Marcus
    Ocheltree, Scott M.
    Wondmagegnehu, Eshetu T.
    Morrow, Linda A.
    Kollmeier, Alexa P.
    Campaigne, Barbara N.
    Jacober, Scott J.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (11) : 2679 - 2687
  • [8] Similar progression of diabetic retinopathy with glargine or NPH insulin in type 2 diabetes (T2D)
    Rosenstock, Julio
    Fonseca, Vivian
    McGill, Janet
    Riddle, Matthew
    Halle, Jean-Pierre
    Hramiak, Irene
    Johnston, Peter
    Davis, Matthew
    [J]. DIABETES, 2008, 57 : A86 - A86
  • [9] Comparing Insulin Glargine (GLAR) with Insulin Detemir (DET)-Effects of A1c Lowering on Weight Change and Insulin Dose in Patients (Pts) with Type 2 Diabetes (T2D)
    Dailey, George
    Admane, Karim
    Mercier, Florence
    Owens, David
    [J]. DIABETES, 2009, 58 : A128 - A128
  • [10] Insulin Glargine (GLAR) and NPH Insulin (NPH) in Real Life in Russia in Patients with Type 2 Diabetes (T2D)
    Shestakova, Marina V.
    Glinkina, Irina V.
    [J]. DIABETES, 2009, 58 : A530 - A530
12345